Past, Present and Future: SGLT2 inhibitors for CV Outcomes

Published: 17 August 2020

  • Views:

    Views Icon 616
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 1
    How Did We Get Here?
    Andrew JS Coats, Faiez Zannad, Stefan Anker, John JV McMurray
    Up Next
  • episode_image
    18m 32s
    Part 2 Where Are We Now?
    Andrew JS Coats, Faiez Zannad, Stefan Anker, John JV McMurray
  • episode_image
    14m 39s
    Part 3 What Is the Future?
    Andrew JS Coats, Faiez Zannad, Stefan Anker, John JV McMurray
Average (ratings)
No ratings
Your rating

Overview

This roundtable event includes four leading heart failure specialists discussing recent data related to SGLT2 inhibitors in reducing CV risk, HF hospitalisations and mortality and morbidity in HFrEF irrespective of T2DM. The panel also look at ongoing studies including those for HFpEF and CKD outcomes.

 

This video series was funded by an unrestricted educational grant from Boehringer Ingelheim.

Educational Objectives

  • Understand the History of SGLT2 Inhibitors and the Published Data from SGLT-2 Inhibitor Cardiovascular Outcome Trials (CVOT).
  • Link These Outcomes Data to the Latest Guideline Updates in Diabetes.
  • Understand the Importance of the Ongoing CREDENCE, EMPA and DAPA Clinical Trials.
  • Evaluate Emerging Data of the Treatment of HF With SGLT2 Inhibitors in Patients With or Without T2DM.
  • Apply This Clinical Understanding to the Management of Heart Failure Patients in the Real World.
  • Identify Important Future Developments to Be Aware of to Allow Continual Optimisation of Heart Failure Management and the Potential for Future Guideline Updates in Heart Failure
  • Assess the Interrelationships Linking Diabetes, HF and CVD

More from this programme

Part 1

How Did We Get Here?

Test description

Part 2

Where Are We Now?

Part 3

What Is the Future?

Faculty Biographies

Andrew JS Coats

Andrew JS Coats

Professor of Cardiology and Scientific Director

Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.

Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.

He is an…

View full profile
Faiez Zannad

Faiez Zannad

Professor of Therapeutics and Cardiology, Head of CIC

Prof Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).

Prof Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension. 

Prof Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.

View full profile
Stefan Anker

Stefan Anker

Professor of Cardiology

Prof Stefan Anker is professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. Prodigious researcher who has authored more than 1,000 articles. He has also won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. In October 2020, he was awarded a Doctor honoris causa of Medical University Wroclaw, Poland.

Prof Anker has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006 and was HFA President from 2012 to 2014. He currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open-access heart failure journal, ESC Heart Failure. Prof. Anker has served on several ESC Guideline task forces.

Prof Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) and founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and…

View full profile
John JV McMurray

John JV McMurray

Professor of Cardiology

Prof John McMurray is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. A graduate of Manchester University, Prof McMurray completed postgraduate research at the University of Dundee.

Prof McMurray is a Fellow of the European Society of Cardiology (ESC), American College of Cardiology and American Heart Association as well as the medical Royal Colleges in Edinburgh and Glasgow and the Royal Society of Edinburgh and UK Academy of Medical Sciences.

View full profile